HealthcareServices

Gout Therapeutics Market Report 2026: Strategic Insights and Revenue Outlook

February 25, 2026 by Marketing Posting

Uncover key drivers, emerging technologies, and competitive movements shaping the gout therapeutics market from 2026–2035 with trusted insights from The Business Research Company

What size range is anticipated for the Gout Therapeutics Market from 2026 to 2030?

The gout therapeutics market has observed significant expansion in recent years. Its size is expected to escalate from $3.22 billion in 2025 to $3.59 billion in 2026, reflecting a compound annual growth rate (CAGR) of 11.6%. Historically, this growth can be attributed to evolving dietary lifestyle changes, the accessibility of NSAIDs, an uptick in arthritis diagnoses, the provision of hospital rheumatology services, and the progression in pain management drug development.

The gout therapeutics market is projected to experience swift expansion over the coming years, reaching a valuation of $5.6 billion by 2030, propelled by a compound annual growth rate (CAGR) of 11.8%. This anticipated growth during the forecast period is primarily driven by factors such as an expanding aging population, the increasing burden of chronic diseases, advancements in preventive arthritis care, enhanced patient compliance tools, and the adoption of personalized treatment strategies. Key trends expected during the forecast timeframe encompass the increasing prevalence of arthritis linked to lifestyle factors, a surge in the application of uric acid-lowering therapies, the broadening scope of chronic gout management, heightened recognition of the importance of early diagnosis, and advancements in long-term disease monitoring.

Access Your Free Sample Report for In-Depth Market Insights:

https://www.thebusinessresearchcompany.com/sample.aspx?id=12118&type=smp

What Drivers Are Affecting Demand In The Gout Therapeutics Market?

The increasing prevalence of gout is anticipated to drive expansion in the gout therapeutics market moving ahead. Gout is defined as an inflammatory arthritis disorder leading to discomfort and swelling in articulations. This growing incidence of gout largely stems from obesity and metabolic syndrome, conditions that elevate uric acid concentrations in the bloodstream, resulting in the development of urate crystals within joints. Gout therapeutics are instrumental in diminishing the frequency and intensity of gout attacks by decreasing uric acid levels, controlling inflammation, and averting recurrent episodes. For example, in June 2025, a publication cited by PubMed Central, a U.S.-based hub for biomedical and life sciences journals, indicated that by 2050, age-standardized gout incidence and prevalence rates are forecast to climb even higher, signifying the escalating global burden of the condition. Furthermore, in June 2024, data from The National Library of Medicine (NLM), the largest US-based biomedical library, revealed that in 2023, the coexistence of gout and chronic kidney disease (CKD) in the USA affected 7.9 million individuals, with projections suggesting a 29% increase to 9.6 million by 2035 under the baseline scenario. Consequently, the increasing occurrence of gout is acting as a significant catalyst for the expansion of the gout therapeutics market.

Which Segment Groups Are Influencing The Gout Therapeutics Market?

The gout therapeutics market covered in this report is segmented –

1) By Type: Nonsteroidal Anti-Inflammatory Drugs (NSAIDs), Corticosteroid, Diuretics

2) By Treatment: Xanthine Oxidase Inhibitor, Uricosuria Medication

3) By Disease Condition: Acute, Chronic

4) By End-Users: Hospitals, Specialty Clinics, Other End Users

Subsegments:

1) By Nonsteroidal Anti-Inflammatory Drugs (NSAIDs): Traditional NSAIDs, Selective COX-2 Inhibitors

2) By Corticosteroid: Oral Corticosteroids, Injectable Corticosteroids

3) By Diuretics: Thiazide Diuretics, Loop Diuretics

Which Market Trends Are Opening Growth Opportunities In The Gout Therapeutics Market?

Leading companies within the gout therapeutics market are innovating by creating products like urate transporters, which facilitate the reabsorption of uric acid from urine back into the bloodstream. A urate transporter is defined as a protein responsible for moving uric acid (urate) across cell membranes in either the kidneys or intestines, thereby playing a role in regulating blood uric acid concentrations. As an illustration, Eisai Co. Ltd., a pharmaceutical firm based in Japan, introduced URECE (dotinurad) in July 2025; this selective urate transporter 1 (URAT1) inhibitor is being marketed as part of Eisai’s global specialty care portfolio. URECE serves as a treatment for hyperuricemia linked to gout, working by reducing serum uric acid levels through enhanced renal excretion. Furthermore, it presents a desirable safety profile with minimal unwanted effects and demonstrates effectiveness in patients with mild-to-moderate renal impairment, positioning it as an appropriate option for a wide spectrum of gout sufferers.

Who Are The Primary Competitors In The Global Gout Therapeutics Market?

Major companies operating in the gout therapeutics market are Takeda Pharmaceutical Company Ltd, Novartis AG, AstraZeneca plc, GlaxoSmithKline plc, Merck & Co Inc, Regeneron Pharmaceuticals Inc, Teijin Pharma Ltd, Zydus Group, Teva Pharmaceutical Industries Ltd, Sun Pharmaceutical Industries Ltd, Dr Reddy’s Laboratories Ltd, Amneal Pharmaceuticals Inc, Lupin Limited, Ironwood Pharmaceuticals Inc, Pharvaris NV, Selecta Biosciences Inc, Dyve Biosciences Inc, Arthrosi Therapeutics Inc, Atom Therapeutics Co Ltd, Olatec Therapeutics LLC

Access The Complete Report For Deeper Market Insights:

https://www.thebusinessresearchcompany.com/report/gout-therapeutics-global-market-report

Which Regions Are Poised For Strategic Growth In The Gout Therapeutics Market?

North America was the largest region in the gout therapeutics market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the gout therapeutics market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request Your Customized Gout Therapeutics Market Research Report for Competitive Advantage:

https://www.thebusinessresearchcompany.com/customise?id=12118&type=smp

Browse Through More Reports Similar to the Global Gout Therapeutics Market 2026, By The Business Research Company

Anti Inflammatory Therapeutics Market Report 2026

https://www.thebusinessresearchcompany.com/report/anti-inflammatory-therapeutics-global-market-report

Gouty Arthritis Market Report 2026

https://www.thebusinessresearchcompany.com/report/gouty-arthritis-global-market-report

Ursolic Acid Market Report 2026

https://www.thebusinessresearchcompany.com/report/ursolic-acid-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795